icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
Safety of ABT-450/Ritonavir/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and 3 Trials
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Michael Fried1, Adrian M Di Bisceglie2, John Vierling3, Edward Gane4, Frederik Nevens5, Simone I Strasser6, Ola Weiland7, Sorin Rugina8, Sandra Lovell9, Barbara Da Silva-Tillmann9, Nancy Shulman9, Naoky Tsai10, David R Nelson11 1UNC Liver Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; 2Saint Louis University Liver Center, Saint Louis University, St. Louis, Missouri, United States; 3Baylor College of Medicine, St. Luke's Advanced Liver Therapies, Houston, Texas, United States; 4Liver Unit, Auckland City Hospital, Auckland, New Zealand; 5Division of Liver and Biliopancreati c Disorders, University Hospitals KU, Leuven, Belgium; 6AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 7Karolinska University Hospital Huddinge, Karolinska Insti tutet, Stockholm, Sweden; 8Ovidius University Constanta, Infecti ous Diseases Research Department, Constanta, Romania; 9AbbVie Inc., North Chicago, Illinois, United States; 10Queen's Medical Center, University of Hawaii, Honolulu, Hawaii, United States; 11Department of Medicine, University of Florida, Gainesville, Florida, United States










1. Degasperi E and Aghemo A. Hepat Med. 2014;6:25-33.
2. Ward RP and Kugelmas M. Am Fam Physician. 2005;72:655-62.
3. Andreone P, et al. Gastroenterology. 2014;147(2):359-65.
4. Feld JJ, et al. N Engl J Med. 2014;370(17):1594-603.
5. Ferenci P, et al. N Engl J Med. 2014;370(21):1983-92.
6. Kowdley KV, et al. N Engl J Med. 2014;370(3):222-32.
7. Poordad F, et al. N Engl J Med. 2014;370(21):1973-82.
8. Zeuzem S, et al. N Engl J Med. 2014;370(17):1604-14.
9. Lalezari J, et al. IFN-free 3 DAA regimen in HCV genotype 1-infected pati ents on
methadone or buprenorphine. Presented at: Conference on Retroviruses and Opportunisti c Infecti ons; March 3-6, 2014; Boston, MA. 10. Poordad F, et al. N Engl J Med. 2013;368(1):4-53.